Disease Areas:
Refractory Chronic CoughDevice Types:
VitaloJAKDOI:
10.1093/ajrccm/aamag162.2093This post hoc analysis of the Phase 2a RIVER trial evaluated the effect of nalbuphine extended release on cough bouts in patients with refractory chronic cough. The VitaloJAK digital cough monitor was used to objectively collect 24-hour cough frequency data, enabling identification and quantification of cough bouts.
